← Leaderboards
Jason W. Botten
Scripps Research Institute
$9,089,641
Attributed
$13,316,639
Total exposure
13
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,316,639 · 13
By mechanism
U01$3,085,084 · 1
R42$2,949,803 · 1
R01$2,296,696 · 1
U54$1,509,592 · 1
R41$1,390,747 · 2
R21$1,285,306 · 3
Top collaborators
- Sean A Diehl5 shared
- Beth Diane Kirkpatrick5 shared
- Joana M Murad5 shared
- Michael W Fanger2 shared
- Irena Ivanovska1 shared
Most similar at Scripps Research Institute
Same institution · by research overlap
- Michael Buchmeier$13,319,318
- Erica Ollmann Saphire$52,684,297
- Michael B Oldstone$35,619,947
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusInfectionViralVaccinesMapsPathway InteractionsPathogenAntiviral AgentsArenavirusMolecularLymphocytic Choriomeningitis VirusAntibodiesHantavirusRodentViral ProteinsFamilyAnimalsCellsFda ApprovedProteinsGlycoproteinsAmericasPathogenesisNeutralizing Antibody
Grant awards (32)
A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome$955,865
R42 · FY2025 · AI
The role of mammarenavirus defective interfering particles in protecting host fitness and the host-driven post-translational modifications that regulate their formation and function$598,271
R01 · FY2025 · AI · contact PI
A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome$993,938
R42 · FY2024 · AI
The role of mammarenavirus defective interfering particles in protecting host fitness and the host-driven post-translational modifications that regulate their formation and function$613,623
R01 · FY2024 · AI · contact PI
A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome$1,000,000
R42 · FY2023 · AI
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine$608,440
U01 · FY2023 · AI
The role of mammarenavirus defective interfering particles in protecting host fitness and the host-driven post-translational modifications that regulate their formation and function$540,864
R01 · FY2023 · AI · contact PI
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine$608,997
U01 · FY2022 · AI
The role of mammarenavirus defective interfering particles in protecting host fitness and the host-driven post-translational modifications that regulate their formation and function$543,938
R01 · FY2022 · AI · contact PI
A Novel Broad-spectrum Antiviral Agent$290,738
R41 · FY2022 · AI
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine$611,648
U01 · FY2021 · AI
A Novel Broad-spectrum Antiviral Agent$299,916
R41 · FY2021 · AI
Deep sequencing the lymphocytic choriomeningitis arenavirus quasispecies to identify and functionally validate the molecular signature ofdefective interfering particles$195,538
R21 · FY2021 · AI · contact PI
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine$615,445
U01 · FY2020 · AI
Deep sequencing the lymphocytic choriomeningitis arenavirus quasispecies to identify and functionally validate the molecular signature ofdefective interfering particles$248,809
R21 · FY2020 · AI · contact PI
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine$640,554
U01 · FY2019 · AI
Mapping the Zika virus phosphoproteome$193,081
R21 · FY2019 · AI · contact PI
Therapeutic antibodies for treatment of hantavirus cardiopulmonary syndrome$446,014
R41 · FY2018 · AI · contact PI
Mapping the Zika virus phosphoproteome$232,137
R21 · FY2018 · AI · contact PI
Therapeutic antibodies for treatment of hantavirus cardiopulmonary syndrome$54,079
R41 · FY2018 · AI · contact PI
Therapeutic antibodies for treatment of hantavirus cardiopulmonary syndrome$300,000
R41 · FY2017 · AI · contact PI
HANTAVIRUS AND ARENAVIRUS HOST-PATHOGEN INTERACTIONS$248,464
P20 · FY2011 · RR · contact PI
Identification of Novel Arenavirus Protein-Host Cellular Protein Interactions$188,615
R21 · FY2011 · AI · contact PI
HANTAVIRUS AND ARENAVIRUS HOST-PATHOGEN INTERACTIONS$236,624
P20 · FY2010 · RR · contact PI
Identification of Novel Arenavirus Protein-Host Cellular Protein Interactions$227,126
R21 · FY2010 · AI · contact PI
HANTAVIRUS AND ARENAVIRUS HOST-PATHOGEN INTERACTIONS$236,234
P20 · FY2009 · RR · contact PI
Therap Human Monoclonal Antibod for Treatment of Hantavirus Cardiopulmonary Syndr$454,655
U54 · FY2008 · AI · contact PI
Therap Human Monoclonal Antibod for Treatment of Hantavirus Cardiopulmonary Syndr$441,100
U54 · FY2007 · AI · contact PI
Therap Human Monoclonal Antibod for Treatment of Hantavirus Cardiopulmonary Syndr$319,767
U54 · FY2006 · AI · contact PI
Therap Human Monoclonal Antibod for Treatment of Hantavirus Cardiopulmonary Syndr$294,070
U54 · FY2005 · AI
Dynamics of arenavirus gene expression in vivo$31,669
F32 · FY2004 · AI
Dynamics of arenavirus gene expression in vivo$46,420
F32 · FY2003 · AI